• Treatment for mastalgia in the presence of diffuse mastopathy in female patients during the menopausal transition period

Treatment for mastalgia in the presence of diffuse mastopathy in female patients during the menopausal transition period

HEALTH OF WOMAN. 2018.7(133):84–88

Kulagina N. V.
FSBEI of HE «North-West State Medical University. I.I. Mechnikov Ministry of Health of Russia», St. Petersburg
Published: Reproductive endocrinology number 6 (38) / December, 2017

Objective. To evaluate the efficacy and tolerability of Mastodynon® in the treatment of diffuse mastopathy and symptoms of premenstrual syndrome (PMS) in women in the menopausal transition period.

Subjects and methods. A clinical prospective, parallel-group, randomized, monocenter, open-label trial with active control was conducted. The trial included 60 patients (mean age, 49.0±3.1 years) who used Mastodynon® or bromocriptine for 24 weeks.

Results. Hyperprolactinemia was detected in 63.3% of the women suffering from different forms of diffuse mastopathy in the menopausal transition period. There was a statistically significant decrease in prolactin levels at 24 weeks of treatment with Mastodynon® (∆ – 244±95.8 mU/ml) (p<0.001) and bromocryptine (∆ – 226.4±101.5 mU/ml) (p<0.001). The results of therapy with Mastodynon® were comparable to the efficiency of that with bromocryptine (p>0.05). Ultrasound mammography revealed positive changes in the breast structure in 67% of the patients with different forms of diffuse mastopathy treated with Mastodynon® and in 43% of those treated with bromocriptine. There was a decrease in the incidence (92% vs 37%; p<0.001) and severity of mastalgia at month 6 of Mastodynon® treatment, the results of therapy did not differ in the two groups (p>0.05). Treatment with Mastodynon® in patients with different forms of mastopathy concurrent with the symptoms of PMS was more effective than that with bromocryptine in relieving autonomic disorders (p<0.05). Adverse events (AEs) occurred more commonly in the patients receiving bromocriptine (60%); AEs were noted in 7% in the Mastodynon® group (p<0.05).

Conclusion. Mastodynon® that contains Vitex agnus-castus extract is an effective agent with a high safety profile to treat mastalgia and symptoms of PMS in patients with different forms of diffuse mastopathy during the menopausal transition period.

Key words: hyperprolactinemia, cyclical mastalgia, premenstrual syndrome, mastopathy, menopausal transition, clinical trial, Mastodynon®.

REFERENCES

1. Bespalov VG, Travina ML. 2015. Fibrozno-kistoznaya bolezn i risk raka molochnoy zhelezyi (obzor literaturyi). Opuholi reproduktivnoy sistemy 11(4):58–70.

2. Onstad M, Stuckey A. 2013. Benign breast disorders». Obstet Gynecol Clin North Am 40.3:459–73. https://doi.org/10.1016/j.ogc.2013.05.004; PMid:24021252

3. Scurr J, Hedger W, Morris P, Brown N. 2014. The prevalence, severity and impact of breast pain in the general population». Breast J 20.5:508–13. https://doi.org/10.1111/tbj.12305; PMid:25041468

4. Rozhkova NI, Burdina II, Zakirova SB i dr. 2015. Lechenie diffuznyih dobrokachestvennyih zabolevaniy molochnoy zhelezyi i mastodinii. Voprosyi ginekologii, akusherstva i perinatologii 14(4):64-68.

5. Fox EM, Andrade J, Shupnik MA. 2009. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways». Steroids 74.7:622–7. https://doi.org/10.1016/j.steroids.2008.10.014; PMid:18996136 PMCid:PMC2702758

6. Gonzalez L, Zambrano A, Lazaro-Trueba I et al. 2009. Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene 28.10:1298–308. https://doi.org/10.1038/onc.2008.473; PMid:19169277

7. Lyichkova AE, Puzikov AM. 2014. Prolaktin i serotonin. Vestnik RAMN 1–2:38–45.

8. Vuttke V, Zeydlova-Vuttke D, Yarri G, Artyimuk N. 2011. Rol Viteksa svyaschennogo (Vitex agnus castus) v ginekologicheskoy endokrinologii. Ginekologiya 14(1):4–7.

9. Radzinskiy VE, Ordiyants IM, Maslennikova MN, Pavlova EA. 2012. Molochnyie zhelezyi i ginekologicheskie bolezni: ot obschnosti patogeneticheskih vozzreniy k prakticheskim resheniyam. M, Redaktsiya zhurnala StatusPraesens:16.

10. Suturina LV, Popova LN. 2012. Dinamika klinicheskih simptomov i korrektsiya antioksidantnoy nedostatochnosti u zhenschin s diffuznoy mastopatiey pri ispolzovanii preparata Mastodinon®. Akusherstvo i ginekologiya 8(1):56–59.

11. Kubista E, Muller G, Spona J. 1987. Treatment of mastopathies with cyclic mastodynia. Clinical results and hormonal profiles. Rev Fr Gynecol Obstet 82:221–7. PMid:3589362

12. Halaska  M, Raus K, Bles P et al. 1988. Treatment of cyclic mastodynia using an extract of Vitex agnus- castus: results of a double blind comparison with a placebo. Ceska Gynecol 63.5:388–92.

13. Wuttke W, Jarry H, Christoffel V et al. 2003. Chaste tree (Vitex agnus castus) – pharmacology and clinical indications. Phytomedicine 10.4:348–57. https://doi.org/10.1078/094471103322004866; PMid:12809367

14. Jarry H, Spengler B, Wuttke W, Christoffel V. 2006. «In vitro assays for bioactivityguided isolation of endocrine active compounds in Vitex agnus-castus». Maturitas 55 Suppl 1:S26–36. https://doi.org/10.1016/j.maturitas.2006.06.014

15. Jarry H, Leonhardt S, Wuttke W et al. 1991. Agnus castus als dopaminerges Wirkprinzip in Mastodynon®. Z Phytother 12:77–82.

16. Sliutz G, Speiser P, Schultz AM et al. 1993. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res 25.5:253–5. https://doi.org/10.1055/s-2007-1002090; PMid:8330858

17. Wuttke W, Gorcow C, Jarry H. 1995. Dopaminergie compounds in Vitex agnus castus. D. Loew, N. Rietbrock, Hrsg. Phytopharmaka in Forschung und klinischer Anwendung. Darmstadt. Steinkopf :81–91. https://doi.org/10.1007/978-3-642-85434-7_6

18. Hoberg E, Sticher O, Orjala JE, Meier B. 1999. Diterpene aus Agni-casti fructus und ihre Analytik. Z Phytother 20:140–58.

19. Ledina AV, Prilepskaya VN. 2012. Predmenstrualnyiy sindrom: vozmozhnosti negormonalnogo lecheniya. Akusherstvo i ginekologiya 1:75–79.

20. Milewicz A, Gejdel E, Sworen H et al. 1993. Author informationVitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study. Arzneimittelforschung 43.7:752–6. PMid:8369008

21. Sotnikova LS i dr. 2011. Sostoyanie gormonalnoy regulyatsii pri fibrozno-kistoznoy mastopatii. Mat i ditya 1:342–346.